The U.S. Food and Drug Administration (FDA) recently granted approval for two new oral medicines, Nuzolvence (zoliflodacin) and Blujepa (gepotidacin), to treat gonorrhoea, a common sexually transmitted infection, prone to resistance against drugs.
About Gonorrhoea:
It is a preventable and curable sexually transmitted infection (STI) caused by the bacteria Neisseria gonorrhea.
It’s also sometimes called “the clap” or “drip.”
Gonorrhea bacteria can infect the urethra, rectum, female reproductive tract.
Transmission:
It is most commonly spread during vaginal, oral or anal sexual activity.
Gonorrhea can affect people of any age, anatomy, or gender, but it’s particularly common among teens and young adults between the ages of 15 and 24.
Symptoms:
It can cause a sore throat, conjunctivitis, unusual vaginal or penile discharge, and pelvic and genital pain.
Untreated gonorrhoea can cause:
infections affecting the skin, joints,heart (endocarditis), and brain (meningitis)
infertility in both females and males
pelvic inflammatory disease (PID)
epididymitis and prostatitis
Some of these complications can cause permanent damage to health.
Treatment:
Gonorrhoea is treatable and curable with antibiotics.
Dear Student,
You have still not entered your mailing address. Please enter the address where all the study materials will be sent to you. (If applicable).
